Shear, I do understand and share your concern - about folks getting the truth. Back in the Stone Age, my father worked in a few campaigns, Tip O'Neill's to drop one name. Years ago, I had two "political" jobs, one with the state of Mass. - and one with Middle*_*_*_*_*_* County, - as a "thank you" for my efforts in campaigns. In a small way, I have seen how campaigns are run, - and BO is good, he really is, but he's NOT telling folks - "the rest of the story", even if you don't want to believe that. ... What he's trying to do is HUGE, - and it's going to be difficult. There WILL BE rationing, NO MATTER what is said today. ... There's NO WAY he can get this thing off the ground by saying anything about rationing, - he HAS to deny anything related to rationing, or this thing will be dead in 4.9 seconds - and he knows it. ... He wanted Tom Dashel to head this up, - things didn't work out for Tom, - lucky thing for the rest of us. Dashel is a HUGE fan of the British system - and good old Tom has stated his views on "cost effectiveness" studies. ... In health care - "clinical effectiveness & cost effectiveness" are often in conflict. ... I'm telling you, down the road there WILL BE rationing - its' unavoidable in this type of program - BO just can't run on that for obvious reasons. BO is the type of politician that you have to learn to ignore what he says, - and watch what he does. ... His first choice on this was Tom Dashel - and that says it all.
.
UK Kidney Cancer Patients Face Toxic, Out-dated Treatments With Little Hope Of Change
ScienceDaily (Dec. 9, 2008) — Leading oncologist Professor Tim Eisen has expressed concerns that patients with advanced kidney cancer could be condemned to toxic, barely effective, 20 year-old treatments because the National Institute for Health and Clinical Excellence (NICE) is likely to rule out using all four of the new treatments it has assessed.
.
Science & Society
* Public Health
* Bioethics
* Resource Shortage
.
Writing in the December issue of BJU International, Professor Eisen, from the University of Cambridge, points out that although NICE has put its findings out for consultation, its provisional decision is that sunitinib, sorafenib, temsirolimus and interferon plus bevacizumab are too costly.
A further review is due to be carried out in January 2009, but Professor Eisen fears that NICE - which advises the UK Department of Health - may confirm its provisional advice that none of these treatments should be provided by the UK's National Health Service.
"We had hoped that NICE would approve at least one of these drugs, as they represent a major breakthrough and there are no suitable alternatives for the large majority of the 4,000 or so patients who might be considered for these drugs in the UK" says Professor Eisen.
"Given that sunitinib was investigated as a first line option, it seemed most likely that it would be approved.
"Our hopes were dashed when NICE released its consultation document. It said that although the four drugs they looked at were clinically effective, they were not cost-effective.